1
|
Piniella D, Zafra F. Functional crosstalk of the glycine transporter GlyT1 and NMDA receptors. Neuropharmacology 2023; 232:109514. [PMID: 37003571 DOI: 10.1016/j.neuropharm.2023.109514] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Revised: 03/10/2023] [Accepted: 03/20/2023] [Indexed: 04/03/2023]
Abstract
NMDA-type glutamate receptors (NMDARs) constitute one of the main glutamate (Glu) targets in the central nervous system and are involved in synaptic plasticity, which is the molecular substrate of learning and memory. Hypofunction of NMDARs has been associated with schizophrenia, while overstimulation causes neuronal death in neurodegenerative diseases or in stroke. The function of NMDARs requires coincidental binding of Glu along with other cellular signals such as neuronal depolarization, and the presence of other endogenous ligands that modulate their activity by allosterism. Among these allosteric modulators are zinc, protons and Gly, which is an obligatory co-agonist. These characteristics differentiate NMDARs from other receptors, and their structural bases have begun to be established in recent years. In this review we focus on the crosstalk between Glu and glycine (Gly), whose concentration in the NMDAR microenvironment is maintained by various Gly transporters that remove or release it into the medium in a regulated manner. The GlyT1 transporter is particularly involved in this task, and has become a target of great interest for the treatment of schizophrenia since its inhibition leads to an increase in synaptic Gly levels that enhances the activity of NMDARs. However, the only drug that has completed phase III clinical trials did not yield the expected results. Notwithstanding, there are additional drugs that continue to be investigated, and it is hoped that knowledge gained from the recently published 3D structure of GlyT1 may allow the rational design of more effective new drugs.
Collapse
Affiliation(s)
- Dolores Piniella
- Centro de Biología Molecular Severo Ochoa, Facultad de Ciencias, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain; IdiPAZ, Institute of Health Carlos III (ISCIII), Spain
| | - Francisco Zafra
- Centro de Biología Molecular Severo Ochoa, Facultad de Ciencias, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain; IdiPAZ, Institute of Health Carlos III (ISCIII), Spain.
| |
Collapse
|
2
|
Pei JC, Luo DZ, Gau SS, Chang CY, Lai WS. Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia. Front Psychiatry 2021; 12:742058. [PMID: 34658976 PMCID: PMC8517243 DOI: 10.3389/fpsyt.2021.742058] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 09/02/2021] [Indexed: 12/30/2022] Open
Abstract
Schizophrenia is a severe mental illness that affects ~1% of the world's population. It is clinically characterized by positive, negative, and cognitive symptoms. Currently available antipsychotic medications are relatively ineffective in improving negative and cognitive deficits, which are related to a patient's functional outcomes and quality of life. Negative symptoms and cognitive deficits are unmet by the antipsychotic medications developed to date. In recent decades, compelling animal and clinical studies have supported the NMDA receptor (NMDAR) hypofunction hypothesis of schizophrenia and have suggested some promising therapeutic agents. Notably, several NMDAR-enhancing agents, especially those that function through the glycine modulatory site (GMS) of NMDAR, cause significant reduction in psychotic and cognitive symptoms in patients with schizophrenia. Given that the NMDAR-mediated signaling pathway has been implicated in cognitive/social functions and that GMS is a potential therapeutic target for enhancing the activation of NMDARs, there is great interest in investigating the effects of direct and indirect GMS modulators and their therapeutic potential. In this review, we focus on describing preclinical and clinical studies of direct and indirect GMS modulators in the treatment of schizophrenia, including glycine, D-cycloserine, D-serine, glycine transporter 1 (GlyT1) inhibitors, and D-amino acid oxidase (DAO or DAAO) inhibitors. We highlight some of the most promising recently developed pharmacological compounds designed to either directly or indirectly target GMS and thus augment NMDAR function to treat the cognitive and negative symptoms of schizophrenia. Overall, the current findings suggest that indirectly targeting of GMS appears to be more beneficial and leads to less adverse effects than direct targeting of GMS to modulate NMDAR functions. Indirect GMS modulators, especially GlyT1 inhibitors and DAO inhibitors, open new avenues for the treatment of unmet medical needs for patients with schizophrenia.
Collapse
Affiliation(s)
- Ju-Chun Pei
- Department of Psychology, National Taiwan University, Taipei, Taiwan
| | - Da-Zhong Luo
- Department of Psychology, National Taiwan University, Taipei, Taiwan
| | - Shiang-Shin Gau
- Department of Psychology, National Taiwan University, Taipei, Taiwan
| | - Chia-Yuan Chang
- Department of Psychology, National Taiwan University, Taipei, Taiwan.,Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan
| | - Wen-Sung Lai
- Department of Psychology, National Taiwan University, Taipei, Taiwan.,Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan.,Graduate Institute of Brain and Mind Sciences, National Taiwan University, Taipei, Taiwan
| |
Collapse
|
3
|
Hudson AR, Santora VJ, Petroski RE, Almos TA, Anderson G, Barido R, Basinger J, Bellows CL, Bookser BC, Broadbent NJ, Cabebe C, Chai CK, Chen M, Chow S, Chung DM, Heger L, Danks AM, Freestone GC, Gitnick D, Gupta V, Hoffmaster C, Kaplan AP, Kennedy MR, Lee D, Limberis J, Ly K, Mak CC, Masatsugu B, Morse AC, Na J, Neul D, Nikpur J, Renick J, Sebring K, Sevidal S, Tabatabaei A, Wen J, Xia S, Yan Y, Yoder ZW, Zook D, Peters M, Breitenbucher JG. Azetidine-based selective glycine transporter-1 (GlyT1) inhibitors with memory enhancing properties. Bioorg Med Chem Lett 2020; 30:127214. [PMID: 32527538 DOI: 10.1016/j.bmcl.2020.127214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 04/22/2020] [Accepted: 04/23/2020] [Indexed: 11/24/2022]
Abstract
A strategy to conformationally restrain a series of GlyT1 inhibitors identified potent analogs that exhibited slowly interconverting rotational isomers. Further studies to address this concern led to a series of azetidine-based inhibitors. Compound 26 was able to elevate CSF glycine levels in vivo and demonstrated potency comparable to Bitopertin in an in vivo rat receptor occupancy study. Compound 26 was subsequently shown to enhance memory in a Novel Object Recognition (NOR) behavioral study after a single dose of 0.03 mg/kg, and in a contextual fear conditioning (cFC) study after four QD doses of 0.01-0.03 mg/kg.
Collapse
Affiliation(s)
- Andrew R Hudson
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States.
| | - Vincent J Santora
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Robert E Petroski
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Theresa A Almos
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Gary Anderson
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Richard Barido
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Jillian Basinger
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Chris L Bellows
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Brett C Bookser
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Nicola J Broadbent
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Clifford Cabebe
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Chih-Kun Chai
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Mi Chen
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Stephine Chow
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - De Michael Chung
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Lindsay Heger
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Anne M Danks
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Graeme C Freestone
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Dany Gitnick
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Varsha Gupta
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | | | - Alan P Kaplan
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Michael R Kennedy
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Dong Lee
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - James Limberis
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Kiev Ly
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Chi Ching Mak
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Brittany Masatsugu
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Andrew C Morse
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Jim Na
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - David Neul
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - John Nikpur
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Joel Renick
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Kristen Sebring
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Samantha Sevidal
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Ali Tabatabaei
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Jenny Wen
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Shouzhen Xia
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Yingzhuo Yan
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Zachary W Yoder
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Douglas Zook
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Marco Peters
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - J Guy Breitenbucher
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| |
Collapse
|
4
|
de Bartolomeis A, Manchia M, Marmo F, Vellucci L, Iasevoli F, Barone A. Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia. Front Psychiatry 2020; 11:369. [PMID: 32477178 PMCID: PMC7240307 DOI: 10.3389/fpsyt.2020.00369] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Accepted: 04/14/2020] [Indexed: 12/14/2022] Open
Abstract
Treatment-resistant schizophrenia (TRS) or suboptimal response to antipsychotics affects almost 30% of schizophrenia (SCZ) patients, and it is a relevant clinical issue with significant impact on the functional outcome and on the global burden of disease. Among putative novel treatments, glycine-centered therapeutics (i.e. sarcosine, glycine itself, D-Serine, and bitopertin) have been proposed, based on a strong preclinical rationale with, however, mixed clinical results. Therefore, a better appraisal of glycine interaction with the other major players of SCZ pathophysiology and specifically in the framework of dopamine - glutamate interactions is warranted. New methodological approaches at cutting edge of technology and drug discovery have been applied to study the role of glycine in glutamate signaling, both at presynaptic and post-synaptic level and have been instrumental for unveiling the role of glycine in dopamine-glutamate interaction. Glycine is a non-essential amino acid that plays a critical role in both inhibitory and excitatory neurotransmission. In caudal areas of central nervous system (CNS), such as spinal cord and brainstem, glycine acts as a powerful inhibitory neurotransmitter through binding to its receptor, i.e. the Glycine Receptor (GlyR). However, glycine also works as a co-agonist of the N-Methyl-D-Aspartate receptor (NMDAR) in excitatory glutamatergic neurotransmission. Glycine concentration in the synaptic cleft is finely tuned by glycine transporters, i.e. GlyT1 and GlyT2, that regulate the neurotransmitter's reuptake, with the first considered a highly potential target for psychosis therapy. Reciprocal regulation of dopamine and glycine in forebrain, glycine modulation of glutamate, glycine signaling interaction with postsynaptic density proteins at glutamatergic synapse, and human genetics of glycinergic pathways in SCZ are tackled in order to highlight the exploitation of this neurotransmitters and related molecules in SCZ and TRS.
Collapse
Affiliation(s)
- Andrea de Bartolomeis
- Laboratory of Molecular Psychiatry and Translational Psychiatry, Unit of Treatment Resistant Psychosis, Section of Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology, University School of Medicine of Napoli Federico II, Naples, Italy
| | - Mirko Manchia
- Section of Psychiatry, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.,Department of Pharmacology, Dalhousie University, Halifax, NS, Canada
| | - Federica Marmo
- Laboratory of Molecular Psychiatry and Translational Psychiatry, Unit of Treatment Resistant Psychosis, Section of Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology, University School of Medicine of Napoli Federico II, Naples, Italy
| | - Licia Vellucci
- Laboratory of Molecular Psychiatry and Translational Psychiatry, Unit of Treatment Resistant Psychosis, Section of Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology, University School of Medicine of Napoli Federico II, Naples, Italy
| | - Felice Iasevoli
- Laboratory of Molecular Psychiatry and Translational Psychiatry, Unit of Treatment Resistant Psychosis, Section of Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology, University School of Medicine of Napoli Federico II, Naples, Italy
| | - Annarita Barone
- Laboratory of Molecular Psychiatry and Translational Psychiatry, Unit of Treatment Resistant Psychosis, Section of Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology, University School of Medicine of Napoli Federico II, Naples, Italy
| |
Collapse
|
5
|
Amberg W, Lange UEW, Ochse M, Pohlki F, Behl B, Relo AL, Hornberger W, Hoft C, Mezler M, Sydor J, Wang Y, Zhao H, Brewer JT, Dietrich J, Li H, Akritopoulou-Zanze I, Lao Y, Hannick SM, Ku YY, Vasudevan A. Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors. J Med Chem 2018; 61:7503-7524. [DOI: 10.1021/acs.jmedchem.8b00300] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Willi Amberg
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061 Ludwigshafen, Germany
| | - Udo E. W. Lange
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061 Ludwigshafen, Germany
| | - Michael Ochse
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061 Ludwigshafen, Germany
| | - Frauke Pohlki
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061 Ludwigshafen, Germany
| | - Berthold Behl
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061 Ludwigshafen, Germany
| | - Ana Lucia Relo
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061 Ludwigshafen, Germany
| | - Wilfried Hornberger
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061 Ludwigshafen, Germany
| | - Carolin Hoft
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061 Ludwigshafen, Germany
| | - Mario Mezler
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061 Ludwigshafen, Germany
| | - Jens Sydor
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Ying Wang
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Hongyu Zhao
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Jason T. Brewer
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Justin Dietrich
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Huanqiu Li
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | | | - Yanbin Lao
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Steven M. Hannick
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Yi-Yin Ku
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Anil Vasudevan
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| |
Collapse
|
6
|
Wang Y, Zhao H, Brewer JT, Li H, Lao Y, Amberg W, Behl B, Akritopoulou-Zanze I, Dietrich J, Lange UEW, Pohlki F, Hoft C, Hornberger W, Djuric SW, Sydor J, Mezler M, Relo AL, Vasudevan A. De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors. J Med Chem 2018; 61:7486-7502. [PMID: 29969029 DOI: 10.1021/acs.jmedchem.8b00295] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The development of glycine transporter 1 (GlyT1) inhibitors may offer putative treatments for schizophrenia and other disorders associated with hypofunction of the glutaminergic N-methyl-d-aspartate (NMDA) receptor. Herein, we describe the synthesis and biological evaluation of a series of 3,4-disubstituted pyrrolidine sulfonamides as competitive GlyT1 inhibitors that arose from de novo scaffold design. Relationship of chemical structure to drug-drug interaction (DDI) and bioactivation was mechanistically investigated. Murine studies were strategically incorporated into the screening funnel to provide early assessments of in vivo target occupancy (TO) by ex vivo binding studies. Advanced compounds derived from iterative structure-activity relationship (SAR) studies possessed high potency in ex vivo binding studies and good brain penetration, promising preliminary in vivo efficacy, acceptable preclinical pharmacokinetics, and manageable DDI and bioactivation liabilities.
Collapse
Affiliation(s)
- Ying Wang
- AbbVie Inc. , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Hongyu Zhao
- AbbVie Inc. , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Jason T Brewer
- AbbVie Inc. , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Huanqiu Li
- AbbVie Inc. , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Yanbin Lao
- AbbVie Inc. , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Willi Amberg
- Neuroscience Research , AbbVie Deutschland GmbH & Co. KG , Knollstrasse , 67061 Ludwigshafen , Germany
| | - Berthold Behl
- Neuroscience Research , AbbVie Deutschland GmbH & Co. KG , Knollstrasse , 67061 Ludwigshafen , Germany
| | | | - Justin Dietrich
- AbbVie Inc. , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Udo E W Lange
- Neuroscience Research , AbbVie Deutschland GmbH & Co. KG , Knollstrasse , 67061 Ludwigshafen , Germany
| | - Frauke Pohlki
- Neuroscience Research , AbbVie Deutschland GmbH & Co. KG , Knollstrasse , 67061 Ludwigshafen , Germany
| | - Carolin Hoft
- Neuroscience Research , AbbVie Deutschland GmbH & Co. KG , Knollstrasse , 67061 Ludwigshafen , Germany
| | - Wilfried Hornberger
- Neuroscience Research , AbbVie Deutschland GmbH & Co. KG , Knollstrasse , 67061 Ludwigshafen , Germany
| | - Stevan W Djuric
- AbbVie Inc. , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| | - Jens Sydor
- Neuroscience Research , AbbVie Deutschland GmbH & Co. KG , Knollstrasse , 67061 Ludwigshafen , Germany
| | - Mario Mezler
- Neuroscience Research , AbbVie Deutschland GmbH & Co. KG , Knollstrasse , 67061 Ludwigshafen , Germany
| | - Ana Lucia Relo
- Neuroscience Research , AbbVie Deutschland GmbH & Co. KG , Knollstrasse , 67061 Ludwigshafen , Germany
| | - Anil Vasudevan
- AbbVie Inc. , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
| |
Collapse
|
7
|
Santora VJ, Almos TA, Barido R, Basinger J, Bellows CL, Bookser BC, Breitenbucher JG, Broadbent NJ, Cabebe C, Chai CK, Chen M, Chow S, Chung DM, Crickard L, Danks AM, Freestone GC, Gitnick D, Gupta V, Hoffmaster C, Hudson AR, Kaplan AP, Kennedy MR, Lee D, Limberis J, Ly K, Mak CC, Masatsugu B, Morse AC, Na J, Neul D, Nikpur J, Peters M, Petroski RE, Renick J, Sebring K, Sevidal S, Tabatabaei A, Wen J, Yan Y, Yoder ZW, Zook D. Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties. J Med Chem 2018; 61:6018-6033. [DOI: 10.1021/acs.jmedchem.8b00372] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Vincent J. Santora
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Theresa A. Almos
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Richard Barido
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Jillian Basinger
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Chris L. Bellows
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Brett C. Bookser
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - J. Guy Breitenbucher
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Nicola J. Broadbent
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Clifford Cabebe
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Chih-Kun Chai
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Mi Chen
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Stephine Chow
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - De Michael Chung
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Lindsay Crickard
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Anne M. Danks
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Graeme C. Freestone
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Dany Gitnick
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Varsha Gupta
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Christine Hoffmaster
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Andrew R. Hudson
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Alan P. Kaplan
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Michael R. Kennedy
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Dong Lee
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - James Limberis
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Kiev Ly
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Chi Ching Mak
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Brittany Masatsugu
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Andrew C. Morse
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Jim Na
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - David Neul
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - John Nikpur
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Marco Peters
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Robert E. Petroski
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Joel Renick
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Kristen Sebring
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Samantha Sevidal
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Ali Tabatabaei
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Jenny Wen
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Yingzhuo Yan
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Zachary W. Yoder
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Douglas Zook
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| |
Collapse
|
8
|
Affiliation(s)
- Christopher L. Cioffi
- Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences , Albany, NY, USA
| |
Collapse
|
9
|
Yamamoto S, Ohta H, Abe K, Kambe D, Tsukiyama N, Kawakita Y, Moriya M, Yasuhara A. Identification of 1-Methyl-N-(propan-2-yl)-N-({2-[4-(trifluoromethoxy)phenyl]pyridin-4-yl}methyl)-1H-imidazole-4-carboxamide as a Potent and Orally Available Glycine Transporter 1 Inhibitor. Chem Pharm Bull (Tokyo) 2017; 64:1630-1640. [PMID: 27803474 DOI: 10.1248/cpb.c16-00610] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
We previously identified 3-chloro-N-{(S)-[3-(1-ethyl-1H-pyrazol-4-yl)phenyl][(2S)-piperidine-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide (5, TP0439150) as a potent and orally available glycine transporter 1 (GlyT1) inhibitor. In this article, we describe our identification of 1-methyl-N-(propan-2-yl)-N-({2-[4-(trifluoromethoxy)phenyl]pyridin-4-yl}methyl)-1H-imidazole-4-carboxamide (7n) as a structurally diverse back-up compound of 5, using central nervous system multiparameter optimization (CNS MPO) as a drug-likeness guideline. Compound 7n showed a higher CNS MPO score and different physicochemical properties as compared to 5. Compound 7n exhibited potent GlyT1 inhibitory activity, a favorable pharmacokinetics profile, and elicited an increase in the cerebrospinal fluid (CSF) concentration of glycine in rats.
Collapse
|
10
|
Talele TT. The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules. J Med Chem 2016; 59:8712-8756. [PMID: 27299736 DOI: 10.1021/acs.jmedchem.6b00472] [Citation(s) in RCA: 565] [Impact Index Per Article: 70.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclinical to clinical stage. Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C-C bonds, (3) enhanced π-character of C-C bonds, and (4) C-H bonds are shorter and stronger than those in alkanes. The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs containing it. Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects,
Collapse
Affiliation(s)
- Tanaji T Talele
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University , 8000 Utopia Parkway, Queens, New York 11439, United States
| |
Collapse
|
11
|
Yamamoto S, Shibata T, Abe K, Oda K, Aoki T, Kawakita Y, Kawamoto H. Discovery of 3-Chloro-<i>N</i>-{(<i>S</i>)-[3-(1-ethyl-1<i>H</i>-pyrazol-4-yl)phenyl][(2<i>S</i>)-piperidine-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide as a Potent Glycine Transporter 1 Inhibitor. Chem Pharm Bull (Tokyo) 2016; 64:1321-37. [DOI: 10.1248/cpb.c16-00314] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
| | | | - Kumi Abe
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd
| | - Koji Oda
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd
| | - Takeshi Aoki
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd
| | - Yasunori Kawakita
- Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd
| | | |
Collapse
|
12
|
Zhao J, Tao H, Xian W, Cai Y, Cheng W, Yin M, Liang G, Li K, Cui L, Zhao B. A Highly Selective Inhibitor of Glycine Transporter-1 Elevates the Threshold for Maximal Electroshock-Induced Tonic Seizure in Mice. Biol Pharm Bull 2016; 39:174-80. [DOI: 10.1248/bpb.b15-00501] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Jianghao Zhao
- Institute of Neurology, Affiliated Hospital of Guangdong Medical University
- Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University
| | - Hua Tao
- Institute of Neurology, Affiliated Hospital of Guangdong Medical University
| | - Wenchuan Xian
- Institute of Neurology, Affiliated Hospital of Guangdong Medical University
| | - Yujie Cai
- Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University
| | - Wanwen Cheng
- Institute of Neurology, Affiliated Hospital of Guangdong Medical University
| | - Mingkang Yin
- Institute of Neurology, Affiliated Hospital of Guangdong Medical University
| | - Guocong Liang
- Institute of Neurology, Affiliated Hospital of Guangdong Medical University
| | - Keshen Li
- Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University
| | - Lili Cui
- Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University
| | - Bin Zhao
- Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University
| |
Collapse
|
13
|
Liu Y, Guo L, Duan H, Zhang L, Jiang N, Zhen X, Shen J. Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors. RSC Adv 2015. [DOI: 10.1039/c5ra04714e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Two series of potential and selective GlyT1 inhibitors were discovered by bioisosteric replacement.23qwas effective on chronic PCP-treated schizophrenia-like behavioral models.
Collapse
Affiliation(s)
- Yang Liu
- State Key Laboratory of Drug Research
- Shanghai Institute of Materia Medica
- Chinese Academy of Sciences
- Shanghai 201203
- China
| | - Lin Guo
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Department of Pharmacology
- Soochow University
- Suzhou 215006
- China
| | - Hongliang Duan
- State Key Laboratory of Drug Research
- Shanghai Institute of Materia Medica
- Chinese Academy of Sciences
- Shanghai 201203
- China
| | - Liming Zhang
- State Key Laboratory of Drug Research
- Shanghai Institute of Materia Medica
- Chinese Academy of Sciences
- Shanghai 201203
- China
| | - Neng Jiang
- China Pharmaceutical University
- Nanjing 210009
- China
| | - Xuechu Zhen
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Department of Pharmacology
- Soochow University
- Suzhou 215006
- China
| | - Jianhua Shen
- State Key Laboratory of Drug Research
- Shanghai Institute of Materia Medica
- Chinese Academy of Sciences
- Shanghai 201203
- China
| |
Collapse
|
14
|
Pinard E, Alberati D, Alvarez-Sanchez R, Brom V, Burner S, Fischer H, Hauser N, Kolczewski S, Lengyel J, Mory R, Saladin C, Schulz-Gasch T, Stalder H. 3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors. ACS Med Chem Lett 2014; 5:428-33. [PMID: 24900853 DOI: 10.1021/ml500005m] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2014] [Accepted: 02/04/2014] [Indexed: 11/29/2022] Open
Abstract
3-Amido-3-aryl-piperidines were discovered as a novel structural class of GlyT1 inhibitors. The structure-activity relationship, which was developed, led to the identification of highly potent compounds exhibiting excellent selectivity against the GlyT2 isoform, drug-like properties, and in vivo activity after oral administration.
Collapse
Affiliation(s)
- Emmanuel Pinard
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Daniela Alberati
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Ruben Alvarez-Sanchez
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Virginie Brom
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Serge Burner
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Holger Fischer
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Nicole Hauser
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Sabine Kolczewski
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Judith Lengyel
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Roland Mory
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Christian Saladin
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Tanja Schulz-Gasch
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Henri Stalder
- Pharmaceutical Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| |
Collapse
|
15
|
GlyT-1 Inhibitors: From Hits to Clinical Candidates. SMALL MOLECULE THERAPEUTICS FOR SCHIZOPHRENIA 2014. [DOI: 10.1007/7355_2014_53] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
16
|
Sanabria-Bohórquez SM, Joshi AD, Holahan M, Daneker L, Riffel K, Williams M, Li W, Cook JJ, Hamill TG. Quantification of the glycine transporter 1 in rhesus monkey brain using [18F]MK-6577 and a model-based input function. Neuroimage 2011; 59:2589-99. [PMID: 21930214 DOI: 10.1016/j.neuroimage.2011.08.080] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2011] [Revised: 08/23/2011] [Accepted: 08/25/2011] [Indexed: 10/17/2022] Open
Abstract
BACKGROUND Glycine transporter 1 (GlyT1) inhibitors have emerged as potential treatments for schizophrenia due to their potentiation of NMDA receptor activity by modulating the local concentrations of the NMDA co-agonist glycine. [18F]MK-6577 is a potent and selective GlyT1 inhibitor PET tracer. Although differences in ligand kinetics can be expected between non-human primates and humans, the tracer pre-clinical evaluation can provide valuable information supporting protocol design and quantification in the clinical space. The main objective of this work was to evaluate the in vivo kinetics of [18F]MK-6577 in rhesus monkey brain. Additionally, a method for estimating the tracer input function from the tracer brain tissue kinetics and venous sampling was validated. This technique was applied for determination of the dose-occupancy relationship of a GlyT1 inhibitor in monkey brain. METHODS Compartmental and Logan graphical analysis were utilized for quantification of the [18F]MK-6577 binding using the measured tracer arterial input function. The stability of the tracer volume of distribution relative to scan length was assessed. The proposed model-based input function method takes advantage of the agreement between the tracer concentration in arterial and venous plasma from ~5 min. The approach estimates the initial peak of the input curve by adding a gamma like function term to the measured venous curve. The parameters of the model function were estimated by simultaneously fitting several brain time activity curves to a compartmental model. RESULTS Good agreement was found between the model-based and the measured arterial plasma curve and the corresponding distribution volumes. The Logan analysis was the preferred method of analysis providing reliable and stable volume of distribution and occupancy results using a 90 and possibly 60 min scan length. CONCLUSION The model-based input function method and Logan analysis are well suited for quantification of [18F]MK-6577 binding and GlyT1 occupancy in monkey brain.
Collapse
|